Monopar Therapeutics (MNPR) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.72

Estimate

-$0.85

Surprise

+15.6%

Score today

5.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Monopar Therapeutics (MNPR) reported a narrower loss than forecast — adjusted EPS of -$0.72 against the -$0.85 estimate (a 15.6% beat on a still-unprofitable quarter).

• JonesTrading Maintains Buy Rating and $130 Price Target for Monopar Therapeutics — fiscal.ai, 2026-11-14
• Cantor Fitzgerald Upgrades Monopar Therapeutics to Overweight — fiscal.ai, 2026-11-14
• Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-12

TrendMatrix currently rates MNPR Sell at 5.6/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +15.6% surprise compares with a +12.4% four-quarter average. Next scheduled report: 2027-03-18.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$72.00

Price target

$113.25

Stop

$66.96

Upside to target

+57.3%

Reward-to-risk

3.9:1

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$487.9M

P/E (fwd)

-24.2

52-week range

$50.07–$124.82

Off 52-week high

42.3%

RSI (14)

52

Volume vs avg

1.39×

Score today

5.6/10